Alzheon to Present at the 2016 JMP Securities Life Sciences Conference

FRAMINGHAM, Mass., June 16, 2016 – Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016, at 12:30 pm at the St. Regis Hotel in New York, NY.

About Alzheon
Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been tested in clinical trials involving over 2,000 Alzheimer’s patients. Our mission is to apply our clinical expertise and technology platform to develop novel therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.

Media Contact:
Kathryn Morris
The Yates Network
Tel: 845‐635‐9828
kathryn@theyatesnetwork.com

2016-11-18T12:35:29+00:00 June 16th, 2016|